Malignant Mesothelioma Market: Industry trends, Drugs, Companies and Analysis by DelveInsight | SELLAS Life Sciences, Takeda, AstraZeneca, Targovax, Aduro Biotech and Others

Malignant Mesothelioma Market: Industry trends, Drugs, Companies and Analysis by DelveInsight | SELLAS Life Sciences, Takeda, AstraZeneca, Targovax, Aduro Biotech and Others

“Malignant Mesothelioma Market”

Malignant Mesotheliomais a relatively rare but aggressive form of cancer most frequently a result of inhaling asbestos arising from the membrane covering the lungs and the inner side of the ribs. The symptoms of MM include breathlessness, cough, chest pain, fatigue, fevers, persistent cough, loss of appetite and unexplained weight loss, swollen figures and constipation. There is an extremely poor prognosis and a vast majority of MM patients who are diagnosed in an advanced stage.

DelveInsight’s “Malignant Mesothelioma Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Malignant Mesothelioma, historical and forecasted epidemiology as well as the Malignant Mesothelioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Some of the key facts of the Malignant Mesothelioma Report:

  1. The annual incidence of Mesothelioma in the United States is estimated to be approximately 3,300 cases per year.
  2. Around 70% of MM develops from documented asbestos exposure, usually after a 30–40 years latency period.
  3. Malignant Mesothelioma (MM) is a rare tumor with an incidence
  4. In Europe, the average incidence of MM is 20 per million inhabitants/year


Request for Free Sample Pages:


Key benefits of the Malignant Mesothelioma Report :

1. Malignant Mesothelioma market report covers a descriptive overview and comprehensive insight of the Malignant Mesothelioma epidemiology and Malignant Mesothelioma  market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. Malignant Mesothelioma market report provides insights on the current and emerging therapies. 

3. Malignant Mesothelioma market report offers a global historical and forecasted market covering drug outreach in 7 MM.

4. Malignant Mesothelioma market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Malignant Mesothelioma market.


Request for Free Sample Pages:

“As per DelveInsight’s analysts, men are more often affected than women, and the incidence in males in the US is 1.5 per 100,000 per year.”


Some of Malignant Mesothelioma Companies are:

  • SELLAS Life Sciences Group
  • Takeda
  • AstraZeneca
  • Targovax
  • Aduro Biotech
  • And Many Others.


Request for Free Sample Pages:


The launch of the emerging therapies is expected to significantly impact the Malignant Mesothelioma treatment scenario in the upcoming years:-

Malignant Mesothelioma Therapies Covered:

  • Galinpepimut‐S
  • Alisertib
  • Tremelimumab
  • ONCOS‐102
  • CRS‐207
  • And Many Others.


Request for Free Sample Pages:


Table Of Contents:

1. Key Insights

2. Malignant Mesothelioma: Market Overview at a Glance

3. Malignant Mesothelioma: Disease Background and Overview

4. Epidemiology and Patient Population

5. Total Cases of Malignant Mesothelioma in 7MM

6. United States Epidemiology

7. EU5 Epidemiology

8. Japan Epidemiology

9. Treatment and Management of Malignant Mesothelioma

10. Unmet Needs

11. Emerging Therapies

12. Malignant Mesothelioma: 7MM Market Analysis

13. United States: Market Outlook

14. EU-5 countries: Market Outlook

15. United Kingdom Market Size

16. Japan Market Outlook

17. Market Drivers

18. Market Barriers

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

Request for Detailed TOC:


Related Reports:

Malignant Mesothelioma Pipeline

The Malignant Mesothelioma report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Malignant Mesothelioma across the complete product development cycle, including all clinical and nonclinical stages.

Malignant Mesothelioma Epidemiology

The Malignant Mesothelioma epidemiology covered in the report provides historical as well as forecasted Malignant Mesothelioma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.


About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States